A major extension to the Autism Spectrum Disorder (ASD) hub, Ostia, at Good Counsel College in New Ross has been given the green light.

As for Fiorentina, Stefano Pioli is still winless in Serie A since his return to the club. As he waved his arms in the air on ...

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

The FDA has approved Palsonify™ (paltusotine) for adults with acromegaly who did not respond adequately to surgery or are not ...

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European ...

Crinetics’ PALSONIFY wins FDA approval as a new oral treatment for acromegaly, offering rapid, effective symptom control.

From operational overhauls to product design, biomanufacturing and bioprocessing companies reduce their environmental impact.

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

Good morning. The government is shut down, but the First Opinion Podcast is back. Take a listen.

Malicious browser extensions are a widespread problem. Even vetted extensions can be dangerous. Here's what you should do to avoid issues. Koi Security investigated a single malicious extension used ...